Generic Drug Makers India
- All
- News
-
Trump's 100% Tariff On Pharma Will Not Impact Generic Makers: Industry Leaders
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
-
Merck COVID-19 Pill Has Vital Indian Link, Maker Sees Stock Price Jump
India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
Lupin Looks To Clean Up Its Act As FDA Steps Up Inspections
Often dubbed "the pharmacy of the world", India is home to the most FDA-approved plants outside of the United States
-
India's 100 Richest Includes Only 4 Women
Four women feature in this year's Forbes list of 100 richest Indians including O P Jindal group Chairperson Savitri Jindal and generic drugs maker USV Pharma Chairperson Leena Tewari.
-
Ranbaxy, Teva settle New York antitrust drug claims
Generic drug makers Ranbaxy of India and Teva of Israel have agreed to settle allegations they made an illegal pact to restrict competition in New York state.
-
Ranbaxy whistle-blower says drug maker faked data
An Indian origin whistle-blower, who exposed a massive fraud by Ranbaxy, has accused the drug maker of faking test results for approval by the US drug regulator.
-
Trump's 100% Tariff On Pharma Will Not Impact Generic Makers: Industry Leaders
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
-
Merck COVID-19 Pill Has Vital Indian Link, Maker Sees Stock Price Jump
India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
-
Hyderabad-Based Hetero Prices Generic COVID-19 Drug At Rs 5,400 Per Vial
Hyderabad-based Hetero Labs Ltd has priced its generic version of remdesivir, Gilead's experimental COVID-19 drug, at Rs 5,400 ($71) per 100-milligram vial, the drug maker said on Wednesday, as it prepares to ship them to hospitals in the country.
-
Lupin Looks To Clean Up Its Act As FDA Steps Up Inspections
Often dubbed "the pharmacy of the world", India is home to the most FDA-approved plants outside of the United States
-
India's 100 Richest Includes Only 4 Women
Four women feature in this year's Forbes list of 100 richest Indians including O P Jindal group Chairperson Savitri Jindal and generic drugs maker USV Pharma Chairperson Leena Tewari.
-
Ranbaxy, Teva settle New York antitrust drug claims
Generic drug makers Ranbaxy of India and Teva of Israel have agreed to settle allegations they made an illegal pact to restrict competition in New York state.
-
Ranbaxy whistle-blower says drug maker faked data
An Indian origin whistle-blower, who exposed a massive fraud by Ranbaxy, has accused the drug maker of faking test results for approval by the US drug regulator.
